Wednesday 6-25-2014 Achillion Pharmaceuticals (ACHN) $ACHN

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
Wednesday 6-25-2014 Achillion Pharmaceuticals (ACHN) $ACHN opened at 7.58 hitting the high price of 7.64 and a day low of 7.26 with a total volume of 4,696,053. ACHN had a previous close of 7.59 and has been seeing an average volume of 15,294,885.

Overall Average: 80% Buy

Recent stock forum discussions about ACHN http://investorshangout.com/search?q=ACHN&...mp;yt0=Go!

Achillion
at Investor's Business Daily - Fri Jun 20, 5:38PM CDT
Achillion (ACHN) shares rose 0.6% to 8.13 after R. W. Baird noted that Merck's (MRK) official tender offer indicated that there was another bidder for Idenix Pharmaceuticals, which means that a company is still looking for a nucleoside hepatitis C... (full story)

Achillion Could Win Idenix's Mystery Suitor: Analyst
at Investor's Business Daily - Fri Jun 20, 11:44AM CDT
Hot biotech stock Achillion Pharmaceuticals (ACHN) was up 2%, near 8.20, in midday trading in the stock market today after an analyst found more support for its prospects as a buyout candidate. R. W. Baird's Brian Skorney noted that Merck's (MRK)... (full story)

The Zacks Analyst Blog Highlights: Idenix, Achillion Pharmaceuticals, Nektar, Orexigen, Celgene, Alexion and Biogen
PR Newswire - Thu Jun 19, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Idenix (Nasdaq:IDIX-Free Report), Achillion Pharmaceuticals (Nasdaq:ACHN-Free Report), Nektar (Nasdaq:NKTR-Free Report), Orexigen (Nasdaq:OREX-Free Report), Celgene (Nasdaq:CELG-Free Report), Alexion (Nasdaq:ALXN-Free Report) and Biogen (Nasdaq:BIIB-Free Report). (full story)

Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 18, 9:33AM CDT
It was about hepatitis C cirus (HCV) treatments and companies last week with the Merck-Idenix acquisition announcement grabbing eyeballs. (full story)

Nasdaq stocks posting largest volume increases
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading: (full story)

Nasdaq stocks posting largest percentage increases
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: (full story)

Most active Nasdaq-traded stocks
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading: (full story)

Critical Alerts For Bank of America, Achillion Pharmaceuticals, Walmart, SunEdison, and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - Tue Jun 17, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BAC, ACHN, WMT, SUNE, and AMD. (full story)

Achillion Gets Massive Price Target Hike On HCV Drugs
at Investor's Business Daily - Mon Jun 16, 10:18PM CDT
Biotech Achillion Pharmaceuticals (ACHN) got another boost Monday when Maxim Group more than tripled its price target on the stock, sending shares up 21% on the stock market today. After having dinner with company executives, analyst Jason Kolbert... (full story)

Achillion gets price target hike
at Investor's Business Daily - Mon Jun 16, 5:56PM CDT
The biotech company's shares soared 20.9% to 7.82 after Maxim Group more than tripled its price target on Achillion Pharmaceuticals (ACHN) stock. Analyst Jason Kolbert increased his target to 22 from 6 on the potential of hepatitis C drug candidates,... (full story)

Why Fusion-io, Achillion Pharmaceuticals, and Covidien Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Mon Jun 16, 4:15PM CDT
Following the first down week for the broad-based S&P 500  in quite some time investors were looking for something positive to start their work week, and a bevy of economic data gave them what they were looking for. Industrial production... (full story)

Why Achillion Pharmaceuticals (ACHN) Is Spiking Today
at The Street - Mon Jun 16, 9:33AM CDT
Achillion Pharmaceuticals (ACHN) is rocketing up after having its price target raised significantly to $22 from $6 by analysts at Maxim. (full story)

3 Stocks That Soared Stupendously This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Jun 15, 8:15AM CDT
How would you like a 40% gain in one week? How about gains of over 120% -- or more than 220%? Shareholders of three health-care stocks don't have to wonder how they'd like those types of returns. They experienced the joy first-hand. One of this... (full story)

This Week in Biotech: Actions Speak Louder Than Words
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 14, 10:20AM CDT
With the  SPDR S&P Biotech Index  up  39% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and... (full story)

Today's Top Biotech Stocks to Watch: Achillion Pharmaceuticals, Nektar Therapeutics and Progenics Ph
George Budwell, The Motley Fool - Motley Fool - Fri Jun 13, 8:02AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for  Achillion Pharmaceuticals   ,  Nektar Therapeutics    and  Progenics Pharmaceuticals   .  Achillion falling back down to Earth Shares of hepatitis C... (full story)

Alexion Pharmaceuticals Inc. (ALXN) Stock Research Links

ALXN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 61

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 144

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Air Sealing First: Boosting Home Comfort & Efficiency

Updated Category News Views 69

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 181

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 28

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 80

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 149

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 252

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 96

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 331

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Cisco's Chief Discusses Entry-Level Hiring Trends and AI

Updated Category News Views 192

Cisco's Insights on Entry-Level Hiring Trends The landscape of entry-level job opportunities is seeing a notable shift. Data from an industry student platform reveals a decrease in job postings for recent graduates. The statistics indicate a 16% year-over-year drop in entry-level positions, sparking concern among graduates and job seekers. Understanding the Current Job...

Continue Reading
FMC’s Rimisoxafen: The Game-Changer Amid Weeds' Rebellion

Updated Category News Views 248

FMC's Bold Move in the Herbicide Game Honestly, this takes me back to the dot-com era—not in tech, but in agriculture. FMC Corporation (NYSE:FMC) just pulled a doozy by getting rimisoxafen classified as a dual mode of action herbicide. This baby’s not just a gimmick; it’s a big deal for a sector that's wrestling down weeds like Palmer amaranth that’ve become a...

Continue Reading
Chord Energy Announces Earnings Call for Q2 2025 Results

Updated Category News Views 168

Chord Energy Earnings Release and Conference Call Details Chord Energy Corp. (NASDAQ: CHRD) has exciting news as it gears up to announce its financial and operational results for the second quarter of 2025. This announcement is scheduled to occur after the market closes, on an appointed date that follows the pattern of previous releases. Live Webcast and Conference Call...

Continue Reading
TuniTuni Thrives Globally with Unique Storytelling Approach

Updated Category News Views 338

TuniTuni: A Global Pioneer in Toddler Development TuniTuni is redefining early childhood physical education through its innovative approach that combines storytelling with the essential elements of physical movement. Since its inception in 2003, this leading brand has garnered attention in various regions, particularly emphasizing the importance of physical activity for...

Continue Reading
Investigation into Open Lending Holdings for Investor Losses

Updated Category News Views 363

Investigation into Open Lending Holdings for Investor Losses Faruqi & Faruqi, LLP is taking steps to look into potential claims on behalf of investors who have faced considerable losses related to Open Lending Corporation (NASDAQ: LPRO). If you have experienced financial setbacks from your investments in Open Lending, it’s important to know that you're not alone and...

Continue Reading